Taysha Gene Therapies Inc... (TSHA)
NASDAQ: TSHA
· Real-Time Price · USD
2.92
-0.02 (-0.68%)
At close: Aug 15, 2025, 3:59 PM
2.98
1.88%
After-hours: Aug 15, 2025, 07:17 PM EDT
Taysha Gene Therapies Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -26.88M | -21.53M | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M | -117.09M | -24.6M | -17.62M | -55.72M | -26.31M | -33.87M | -50.11M | -50.39M | -51.19M | -40.93M | -32.02M |
Depreciation & Amortization | 277K | 283K | 304K | 294K | 322K | 325K | 366K | 331K | 343K | 331K | 364K | 277K | 274K | 257K | 209K | 166K | 85K | 32K |
Stock-Based Compensation | 3.19M | 3.29M | 3.22M | 3.36M | 3.33M | 3.2M | 1.97M | 2.04M | 2.22M | 1.68M | 4.1M | 4.47M | 4.14M | 5.33M | 4.96M | 5.09M | 4.55M | 3.59M |
Other Working Capital | -772K | -5.48M | -1.1M | -2.1M | -2.67M | -3.68M | -3.62M | -4.18M | -2.56M | -5.36M | 32.09M | 2.1M | -7.61M | -267K | 3.53M | -1.12M | 12.77M | -1.01M |
Other Non-Cash Items | 1.01M | 488K | -442K | 6.14M | 52K | 424K | -57.41M | 3.07M | 4.06M | 428K | 38.02M | 229K | 193K | 1.44M | 2.94M | 1.51M | 194K | 5.5M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -3.93M | 101.07M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 2.23M | -4.56M | -2.6M | -5.88M | -4.28M | 298K | -4.85M | -7.37M | -796K | -5M | 27.51M | -7.32M | -3.94M | 2.28M | 2.03M | 12.5M | 13.28M | 863K |
Operating Cash Flow | -20.18M | -22.02M | -18.31M | -21.61M | -21.5M | -19.82M | -16.12M | -17.95M | -18.77M | -20.18M | 14.28M | -28.66M | -33.21M | -40.8M | -40.26M | -31.93M | -22.82M | -22.04M |
Capital Expenditures | -2K | -378K | 2K | -35K | -201K | -140K | -17K | -3.5M | 48K | -3.9M | -2.31M | -3.02M | -8.11M | -11.43M | -8.52M | -4M | -8.5M | -534K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 64K | 7K | 11K | n/a | n/a | n/a | 7K | 10K | n/a | n/a | -61K | -1M | -250K | -3M | -250K | -500K | -5.5M | n/a |
Investing Cash Flow | 62K | -371K | 13K | -35K | -201K | -140K | -10K | -3.49M | 48K | -3.9M | -2.37M | -3.02M | -8.11M | -11.43M | -8.52M | -4M | -8.5M | -534K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | -3.85M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 9.98M | 29.98M | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -68K | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 118K | -127K | 3K | -64K | -13K | -48K | 24K | -79K | 377K | -370K | 63K | -258K | -489K | -91K | -874K | n/a | n/a | n/a |
Financial Cash Flow | 216.29M | -52K | -357K | 6.59M | 70.47M | -22K | -4.25M | 140.63M | 377K | -370K | 41.67M | -258K | 10.93M | -242K | 9.11M | 29.98M | n/a | n/a |
Net Cash Flow | 196.17M | -22.44M | -18.65M | -15.05M | 48.76M | -19.96M | -20.38M | 119.19M | -18.34M | -24.45M | 53.57M | -31.93M | -30.39M | -52.47M | -39.67M | -5.96M | -31.31M | -22.57M |
Free Cash Flow | -20.18M | -22.4M | -18.31M | -21.65M | -21.7M | -19.96M | -16.13M | -21.45M | -18.72M | -24.09M | 11.97M | -31.68M | -41.32M | -52.23M | -48.78M | -35.94M | -31.31M | -22.57M |